Te Ahumairangi Investment Management Ltd Trims Stake in CVS Health Corporation $CVS

Te Ahumairangi Investment Management Ltd lessened its stake in shares of CVS Health Corporation (NYSE:CVS) by 23.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 53,256 shares of the pharmacy operator’s stock after selling 15,954 shares during the quarter. Te Ahumairangi Investment Management Ltd’s holdings in CVS Health were worth $4,226,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of CVS Health by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock valued at $9,579,508,000 after acquiring an additional 1,824,424 shares in the last quarter. Capital World Investors raised its stake in CVS Health by 2.1% in the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock valued at $5,155,380,000 after purchasing an additional 1,419,575 shares during the last quarter. State Street Corp raised its stake in CVS Health by 0.3% in the 3rd quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator’s stock valued at $4,443,357,000 after purchasing an additional 149,701 shares during the last quarter. Capital International Investors lifted its holdings in CVS Health by 3.4% in the 4th quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock valued at $2,189,793,000 after purchasing an additional 900,153 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of CVS Health by 3.2% during the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock worth $1,831,454,000 after purchasing an additional 760,579 shares during the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health News Roundup

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Health said it is using Fluency’s enterprise AI platform to move autonomous agents from pilot projects into production, a sign it is working to cut administrative costs and improve workflow efficiency across the business. CVS is Using Fluency to Close Enterprise AI Deployment Gap
• Positive Sentiment: Aetna launched “Mental Health on Demand,” which gives members real-time access to care and ongoing support; the company highlighted very fast clinician connection times, underscoring stronger service delivery and potentially better member engagement. Aetna Launches Aetna Mental Health on Demand To Provide Real Time Access to Care and Ongoing Support
• Positive Sentiment: CVS Caremark expanded coverage options for GLP-1 weight-loss medications, a move that may support affordability for members while strengthening the company’s position in a fast-growing and closely watched drug category. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications With Expanded Coverage Options

Insider Activity

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Larry Robbins sold 370,462 shares of CVS Health stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the transaction, the director directly owned 4,824,799 shares in the company, valued at $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,441,551 shares of company stock valued at $323,703,977 over the last 90 days. 0.85% of the stock is currently owned by insiders.

CVS Health Price Performance

CVS Health stock opened at $100.38 on Friday. CVS Health Corporation has a 1 year low of $58.50 and a 1 year high of $100.55. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a 50 day moving average price of $86.32 and a 200 day moving average price of $80.63. The company has a market cap of $128.08 billion, a price-to-earnings ratio of 44.22, a PEG ratio of 0.96 and a beta of 0.62.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. CVS Health’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the business earned $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health’s payout ratio is 117.18%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Mizuho boosted their price objective on shares of CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Monday. DA Davidson lifted their target price on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. JPMorgan Chase & Co. boosted their price target on CVS Health from $101.00 to $111.00 and gave the company an “overweight” rating in a report on Tuesday, May 12th. Sanford C. Bernstein raised their price objective on CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Finally, Royal Bank Of Canada lifted their price objective on CVS Health from $93.00 to $107.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $100.68.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.